EFFICIENCY AND SAFETY OF TREATMENT IN PATIENTS WITH LOW BACK PAIN
- Authors: Magomedova M.1, Kamchatnov P.2
-
Affiliations:
- Central Town Hospital, Izberbash, Republic of Dagestan
- N.I. Pirogov Russian National Research Medical University
- Issue: Vol 27, No 3 (2016)
- Pages: 29-31
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116508
- ID: 116508
Cite item
Open Access
Access granted
Abstract
Low back pain (LBP) is one of the most common musculoskeletal pain syndromes in the population. Many patients need repeated treatment cycles, during which the risk of undesirable side effects increases. The results of using Nolodatak (flupirtine) that has analgesic, myorelaxant, and neuroprotective effects in LBP are analyzed.
Full Text
About the authors
M. Magomedova
Central Town Hospital, Izberbash, Republic of Dagestan
Email: pavkam7@gmail.com
P. Kamchatnov
N.I. Pirogov Russian National Research Medical University
Email: pavkam7@gmail.com
Professor Moscow
References
- Hoy D., March L., Brooks P. et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study // Ann. Rheum. Dis. -2014; 73: 968-74.
- Sivasubramaniam V., Patel H., Ozdemir B. et al. Trends in hospital admissions and surgical procedures for degenerative lumbar spine disease in England: a 15-year time series study // BMJ Open. - 2015; 5: e009011. doi: 10.1136/bmjopen-2015- 009011.
- Vos T., Flaxman A., Naghavi M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. - 2012; 380: 2163-96. 32016 ВРАЧ
- Есин Р.Г., Лотфуллина Н.З., Есин О.Р. Цервикалгия, дорзалгия, люмбалгия. Дифференциальная диагностика, дифференцированная терапия / Казань: ИИЦ УД Президента РТ, 2015; 420 с.
- Ueberall1 A., Eberhardt A., Mueller-Schwefe H. Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice // Int. J. Gen. Med. - 2016; 9: 39-51.
- Brown D., Passmore G. Neural KCNQ (Kv7) channels // Br. J. Pharmacol. -2009; 156 (8): 1185-95.
- Szelenyi I. Flupirtine, a rediscovered drug, revisited // Inflamm. Res. - 2013; 62 (3): 251-8.
- Fleckenstein J., Sittl R., Averbeck B. et al. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial // J. Transl. Med. - 2013; 11: 34-9.
- Kornhuber J., Bleich S., Wiltfang J. et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels // J. Neural. Transm. - 1999; 106 (9-10): 857-67.
- Harish S., Bhuvana K., Bengalorkar M. et al. Flupirtine: Clinical pharmacology // J. Anaesthesiol. Clin. Pharmacol. - 2012; 28 (2): 172-7.
- Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound // Expert Opin. Pharmacother. - 2009; 10 (9): 1495-500.
- Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study // Fortschr. Med. Orig. - 2003; 121 (1): 11-8.
- Worz R., Stroehmann I. Ruckemschmerzen: Leitlinien der medicamentosen therapie // Munch. Med. Wschr. - 2000; 142: 27-33.
- Uberall M., Mueller-Schwefe G., Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study // Curr. Med. Res. Opin. - 2012; 28 (10): 1617-34.
- Камчатнов П.Р. Батышева Т.Т., Ганжула П.А. и др. Применение катадо-лона у больных со спондилогенной дорсопатией // Журн. неврол. и психиат. им. С.С. Корсакова. - 2006; 106 (11): 46-9.
- Douros A., Bronder E., Andersohn F. et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study // Br. J. Clin. Pharmacol. - 2015; 79 (6): 988-99.
- Wörz R. Long-term-treatment of chronic pain patients with flupirtine--on hepatotoxicity and persistent effectiveness from 7 months to 22 years // MMW Fortschr. Med. - 2014; 156 (Suppl. 4): 127-34.
Supplementary files
